Thank you to our speakers, sponsors, and delegates who joined us in Boston, MA for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com
Achieving Efficacy Across Neurological & Inflammatory Diseases with Inflammasome Therapeutics
Exciting developments were on the horizon in the realm of inflammasome therapeutics, with the community greatly anticipating the clinical study results from NodThera, Ventyx, Ventus, Roche, and Novartis expected this Fall.
These ground-breaking studies were poised to be the very first Inflammasome Therapeutic setting a new standard and instilling fresh confidence in the therapeutic potential of targeting the inflammasome.
In amidst of the anticipation, the Inflammasome Therapeutics Summit returned for its 6th year as the premier gathering for over 100 biopharma professionals and leading academics, serving as the cornerstone event for navigating the dynamic and challenging landscape from discovery right through to clinical application. Whether attendees were a seasoned biology expert or clinical professional, this summit provides exclusive clinical insights and the latest breakthroughs in inflammasome research.
It was intentionally designed to be niche and focused, ensuring you don’t get lost in a sea of attendees, and in-depth discussions were prioritized over basic introductions. Attendees partook in advanced tactical and strategic conversations with an engaged audience of inflammasome experts who share their passion and commitment to advancing inflammasome therapeutics to the patients who need them most.
The 2024 Expert Speaker Faculty Included:
Michael Grosso
Vice President & Global Head of Clinical Development, Specialty Medicine
Daiichi Sankyo, Inc.
We Were Proud to Partner with:
Expertise Partner
Expertise Partner
Event Partner
It Was 2024’s Must Attend Inflammasome Summit for the Biopharma Community But Don’t Just Take Our Word for It …
Here’s What Your Industry Colleagues Had to Say:
"Great meeting, very relevant content, many excellent speakers and outstanding networking. A very good start of creating a Inflammasome/NLRP3 focus group/community."
AstraZeneca
"Excellent, focused meeting with great mix of academic, clinical and industrial participation, facilitating great networking opportunities and interesting discussion."
Genentech
"Very good talks on many aspects of inflammasome biology and drug discovery, together with good networking opportunities, has triggered some new project ideas"
Vir Biotechnology
"The topics selected were great and covered the most relevant fields and interest around Inflammasome. A really focused, in-depth knowledge sharing experience."
Merck
